Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 222.50
Bid: 223.50
Ask: 225.00
Change: -2.50 (-1.11%)
Spread: 1.50 (0.671%)
Open: 226.00
High: 227.00
Low: 222.00
Prev. Close: 225.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PureTech Reports New Data From Its Immuno-Oncology Programmes

Tue, 05th Nov 2019 14:54

(Alliance News) - PureTech Health PLC on Tuesday presented a new preclinical data from its wholly-owned immuno-oncology programmes.

The clinical-stage biotechnology company reported continued progress in advancing two fully human monoclonal antibodies, developed to inhibit two foundational immunosuppressive orchestrators, galectin-9 and pathogenic gamma delta-1 T cells.

PureTech said the new data indicated that galectin-9 is not only a potent therapeutic target, but also a potentially relevant biomarker. Across multiple cohorts, galectin-9 was "significantly" increased in blood samples of individuals with primary and metastatic pancreatic cancer, lung tumours, and colorectal carcinoma, compared to healthy individuals.

"These findings validate the importance of galectin-9 in cancer biology and its potency as a target," said George Miller, a PureTech collaborator.

Looking ahead, PureTech said it experts to file an investigational new drug application for galectin-9 in the first half of 2020 and to initiate a phase 1a/1b clinical trial in solid tumours in 2020.

PureTech also presented data on its monoclonal antibody LYT-210 that targets gamma delta-1 T cells whose immunosuppressive features leads to a tumour permissive microenvironment.

The research showed that gamma delta-1 T cells were the most abundant T cell within the studied tumours, which included pancreatic, colorectal, cholangiocarcinoma, and liver cancer, and represented up to 50% of all infiltrating T cells.

In addition, PureTech presented data showing that LYT-210 depletes immunosuppressive gamma delta-1 T cells through cytotoxicity and phagocytosis.

"These data show that gamma delta-1 cells play a key role in suppressing the immune system's ability to attack tumours. LYT-210 is designed to remove and destroy pathogenic gamma delta-1 T cells enabling immune mediated cancer attack. We therefore believe LYT-210 holds significant promise as a potential immunotherapy," said Miller.

PureTech shares were trading 0.4% lower on Tuesday in London at 248.00 pence each.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
19 Mar 2024 16:57

LONDON MARKET CLOSE: European large-caps rise on eve of Fed decision

(Alliance News) - Blue-chip stock prices in Europe closed higher on Tuesday, showing little signs of nerves ahead of Wednesday's Federal Reserve decision and UK inflation reading.

Read more
19 Mar 2024 11:16

PureTech shares jump on USD100 million tender offer proposal

(Alliance News) - PureTech Health PLC on Tuesday said it plans to return USD100 million to shareholders with a tender offer, starting after it publishes its annual report in April.

Read more
19 Mar 2024 09:46

Puretech Health proposes $100m capital return

(Sharecast News) - Biotherapeutics company PureTech Health has proposed a capital return of $100.0m to its shareholders by way of a tender offer.

Read more
13 Mar 2024 12:27

PureTech Health celebrates drug designation for LYT-200 from US FDA

(Alliance News) - PureTech Health PLC on Wednesday touted the efficacy of its acute myeloid leukaemia therapy, after securing a regulatory designation from the US Food & Drug Administration.

Read more
27 Feb 2024 11:28

PureTech notes positive results from Shionogi's EndeavorRx ADHD trial

(Alliance News) - PureTech Health PLC on Tuesday noted that its founded entity, Akili Inc, has announced positive results from a phase 3 clinical trial of EndeavorRx for children with attention deficit hyperactivity disorder in Japan.

Read more
20 Dec 2023 09:53

PureTech makes strong progress, expects "multiple catalysts" next year

(Alliance News) - PureTech Health PLC on Wednesday said it made "strong strategic and clinical progress" in 2023, and predicted "a productive and exciting" tear to come.

Read more
1 Dec 2023 14:29

TRADING UPDATES: N4 launches investor hub; Capricorn production falls

(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News:

Read more
17 Nov 2023 09:44

IN BRIEF: PureTech hails schizophrenia trial results for Karuna drug

PureTech Health PLC - Boston, Massachusetts-based FTSE 250 biotechnology company - Founded entity Karuna Therapeutics reports "positive results" from Phase 1b trial evaluating the effects of xanomeline-trospium, brand name KarXT, on 24-hour ambulatory blood pressure in adults with schizophrenia. Karuna says KarXT does not cause clinically meaningful blood pressure increases, with an average change from baseline at week eight of minus 0.59 mmHg or millimetre of mercury. Other vital signs like average diastolic blood pressure and heart rate were consistent with previous KarXT trials in schizophrenia. Adds that KarXT was generally well-tolerated, and side effects remained consistent with prior trials under the Emergent programme. Karuna in late September announced its application to the US Food & Drug Administration for approval of KarXT to treat schizophrenia; if successful, it will be PureTech's third therapeutic candidate to gain FDA approval. KarXT is also in development to treat psychosis associated with Alzheimer's disease.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
14 Nov 2023 10:59

PureTech Health celebrates positive results in Phase 2 anxiety trial

(Alliance News) - PureTech Health PLC on Tuesday said its therapeutic LYT-300 achieved its primary endpoint for acute anxiety reduction, in a Phase 2a trial using healthy volunteers.

Read more
11 Oct 2023 14:22

IN BRIEF: PureTech's LYT-100 shows 50% improvement to key adverse events

PureTech Health PLC - Boston-based biotechnology company - Says LYT-100 trial shows around 50% improvement in gastrointestinal and central nervous system related adverse events in adults suffering from idiopathic pulmonary fibrosis compared to US Food & Drug Administration-approved pirfenidone. Adds data shows higher dose of LYT-100 well-tolerated with no additional incidence of GI or CNS AEs when titrated up from 550 milligrams dosage.

Read more
4 Oct 2023 13:55

PureTech Health subsidiary receives fast track designation for VE202

(Alliance News) - PureTech Health PLC on Wednesday said its subsidiary Vedanta Biosciences has received fast-track designation for its VE202 treatment.

Read more
28 Sep 2023 15:08

TRADING UPDATES: Rockhopper loss widens; Synectics inks new contract

(Alliance News) - (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
27 Sep 2023 10:40

Arix Bioscience boosts net value, CEO jumping ship for PureTech Health

(Alliance News) - Arix Bioscience PLC on Wednesday said net asset value increased in its latest half year, but has since launched a strategic review due to "unfavourable" conditions while Chief Executive Officer Robert Lyne prepares to step down.

Read more
29 Aug 2023 09:39

PureTech narrows interim loss despite "stormy market challenges"

(Alliance News) - PureTech Health PLC on Tuesday said its half-year loss narrowed, but saw its revenue fall by more than half.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.